Bronchial Spasm Market Analysis

Treatment Type {Short-Acting Bronchodilators (Albuterol, Levalbuterol)

The global bronchial spasm market is segmented and analyzed for demand and supply by treatment type into short-acting bronchodilators (albuterol and levalbuterol), long-acting bronchodilators (aclidinium, salmeterol, formoterol, indacaterol, and others), and inhaled & oral steroids, out of which, the short-acting bronchodilators segment is projected to witness noteworthy growth over the forecast period. The growth of the segment can be accounted to their higher demand to treat asthma attacks and COPD. For instance, about 10 people lose their lives due to asthma each day in the USA, while in 2020, nearly 4000 individuals died due to asthma in a similar region.

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Our in-depth analysis of the global market includes the following segments:

By Treatment Type	Short-Acting Bronchodilators Albuterol Levalbuterol Long-Acting Bronchodilators Aclidinium Salmeterol Formoterol Indacaterol Others Inhaled & Oral Steroids
By Diagnosis	Arterial Blood Gas Tests Chest X-Ray C.T. Scans Others
By Cause	COPD Asthma Chronic Bronchitis Emphysema Others
By End-User	Hospitals Clinics Others

Frequently Asked Questions (FAQ)

Increasing prevalence of fungal infection and rising cases of COPD across the globe are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2033.

Shortage of medication and skilled medical professionals is estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Sunovion Pharmaceuticals Inc., Merck & Co., Inc., Viatris Inc., Pfizer Inc., The Bristol-Myers Squibb Company, Sanofi S.A, Teva Pharmaceutical Industries Ltd. and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment type, diagnosis, cause, end-user, and region.

The short-acting bronchodilators segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Bronchial Spasm Market Analysis